Advances in oncolytic virotherapy

Stephen J. Russell; John C. Bell; Christine E. Engeland; Grant McFadden

doi:10.1038/s43856-022-00098-4

Communications Medicine (Apr 2022)

Advances in oncolytic virotherapy

Stephen J. Russell,
John C. Bell,
Christine E. Engeland,
Grant McFadden

Affiliations

Stephen J. Russell: Mayo Clinic
John C. Bell: Ottawa Hospital Research Institute, University of Ottawa
Christine E. Engeland: Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Grant McFadden: Center for Immunotherapy, Vaccines, and Virotherapy (CIVV), Biodesign Institute, Arizona State University

DOI: https://doi.org/10.1038/s43856-022-00098-4
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 3

Abstract

Read online

Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapies in patients.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal